Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer

作者：Gerber David E^*; Spigel David R; Giorgadze David; Shtivelband Mikhail; Ponomarova Olga V; Shan Joseph S; Menander Kerstin B; Belani Chandra P

来源：Clinical Lung Cancer, 2016, 17(3): 169-176.

DOI：10.1016/j.cllc.2016.02.003

• Immunotherapy
• Macrophages
• Monoclonal antibody
• Phosphatidylserine
• Tumor microenvironment

This phase II trial was intended to investigate 2 doses of bavituximab (a phosphatidylserine-targeting antibody) or placebo combined with docetaxel in previously treated, advanced nonsquamous nonesmall-cell lung cancer. Because of a labeling discrepancy, the placebo and bavituximab 1 mg/kg arms were combined and compared with the bavituximab 3 mg/kg arm. This exploratory analysis showed similar toxicity between arms, and albeit without meeting the preset statistical end points because of the pooled control arm data, had trends favoring bavituximab 3 mg/kg.
Background: Bavituximab is a phosphatidylserine-targeting antibody with a selective tumor, vascular-directed immune response. In this phase II trial the efficacy and safety of bavituximab combined with docetaxel for previously treated, advanced nonsquamous nonesmall-cell lung cancer were evaluated. Patients and Methods: Patients were randomized 1:1:1 to receive docetaxel 75 mg/m(2) every 21 days for up to 6 cycles combined with weekly, blinded infusions of placebo, bavituximab 1 mg/kg, or bavituximab 3 mg/kg until disease progression or unacceptable toxicity. The primary end point was overall response rate (ORR), with a predefined end point of 26% in the bavituximab arms. After study unblinding, vial-coding discrepancies were discovered in the placebo and bavituximab 1 mg/kg groups. In exploratory analyses, data from these groups were pooled to form the control group and compared with the 3 mg/kg group. Results: Efficacy end points in the bavituximab 3 mg/kg group (n = 41) and in the placebo/bavituximab 1 mg/kg group (n = 80), respectively, were as follows: ORR, 17.1% (95% confidence interval [CI], 5.6%-28.6%) and ORR, 11.3% (95% CI, 4.3%-18.2%); median progression-free survival 4.5 and 3.3 months (hazard ratio [HR], 0.74 [95% CI, 0.45-1.21]; P = .24); median overall survival 11.7 and 7.3 months (HR, 0.66 [95% CI, 0.40-1.10]; P = .11). Toxicities were manageable and similar between arms. Conclusion: The combination of bavituximab and docetaxel is well tolerated. Although no firm efficacy conclusions can be drawn and the trial did not meet the predefined primary end point, exploratory analyses suggest trends favoring the combination of bavituximab 3 mg/kg with docetaxel. This regimen is being evaluated in the ongoing, global, phase III SUNRISE trial.

• 出版日期2016-5